KimberlyYSmithMDMPH
Infectious Disease • Durham, NCSenior Vice President, Head of Research and Development, ViiV Healthcare, Durham, NC
Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
n/a
Durham, NC 27709Phone+1 919-491-2167
Education & Training
Rush University Medical CenterFellowship, Infectious Disease, 1996 - 1998- Rush University Medical CenterResidency, Internal Medicine, 1993 - 1996
University of Michigan Medical SchoolClass of 1993
Certifications & Licensure
IL State Medical License 1996 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
Publications & Presentations
PubMed
- 24 citationsOutcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.Kimberly Y. Smith, Camlin Tierney, Katie R. Mollan, Charles S. Venuto, Chakra Budhathoki
Clinical Infectious Diseases. 2014-02-15 - 102 citationsDolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line the...Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A Hidalgo
The Lancet. Infectious Diseases. 2019-03-01 - 306 citationsCabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Deborah Donnell, Meredith E. Clement, Brett Hanscom, Leslie Cottle
The New England Journal of Medicine. 2021-08-11
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
